Diagnostic Yield of Primary Circulating Tumor Cells in Women Suspected of Breast Cancer: the BEST (Breast Early Screening Test) Study
Authors:
- Nigel P MurrayNMNigel P Murray
- Roxana MirandaRMRoxana Miranda
- Amparo RuizARAmparo Ruiz
- Elsa DroguettEDElsa Droguett
Open Access
- 18 March 2015
- journal article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (5) , 1929-1934
Abstract
To determine the diagnostic yield of primary circulating tumor cells in women with suspicion of breast cancer, detected as a result of an abnormal mammography. Consecutive women presenting for breast biopsy as a result of a mammogram BiRADs of 3 or more, had an 8 ml blood sample taken for primary circulating tumor cell (CTC) detection. Mononuclear cells were obtained using differential gel centrifugation and CTCs identified using standard immunocytochemistry using anti-mammoglobin. A test was determined to be positive if 1 CTC was detected. A total of 144 women with a mean age of 54.7 ± 15.6 years participated, 78/144 (53.0%) had breast cancer on biopsy, 65/140 (46.3%) benign pathologies and 1(0.7%) non-Hogkins lymphoma. Increasing BiRADs scores were associated with increased cancer detection (p=0.004, RR 1.00, 4.24, 8.50). CTC mammoglobin positive had a sensitivity of 81.1% and specificity of 90.9%, with positive and negative predictive values of 90.9% and 81.1% respectively. Mammoglobin positive CTCs detected 87% of invasive cancers, while poorly differentiated cancers were negative for mammoglobin. Only 50% of in situ cancers and none of the intraductal cancers had CTCs detected. Menopausal status did not affect the diagnostic yield of the CTC test, which was higher in women with BiRADS 4 mammograms. There was a significant trend (p<0.0001 Chi squared for trends) in CTC detection frequency from intraductal, in situ and invasive (OR 1.00, 8.00, 472.00). The use of primary CTC detection in women suspected of breast cancer has potential uses, especially with invasive cancer, but it failed to detect intra-ductal cancer and 50% of in situ cancer. There was no difference in the diagnostic yield between pre and post menopausal women. To confirm its use in reducing biopsies in women with BIRADs 4a mammagrams and in the detection of interval invasive breast cancer, larger studies are needed.Keywords
This publication has 19 references indexed in Scilit:
- Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancerBreast Cancer Research, 2012
- Human Mammaglobin: A Superior Marker for Reverse-Transcriptase PCR in Detecting Circulating Tumor cells In Breast Cancer PatientsBiomarkers in Medicine, 2011
- Detection of Cytokeratin 19, Human Mammaglobin, and Carcinoembryonic Antigen-Positive Circulating Tumor Cells by Three-Marker Reverse Transcription-Pcr Assay and Its Relation to Clinical Outcome in Early Breast CancerThe International Journal of Biological Markers, 2010
- Forthcoming IssueSeminars in Oncology, 2006
- Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsyCancer, 2005
- Factors Contributing to Mammography Failure in Women Aged 40-49 YearsJNCI: Journal of the National Cancer Institute, 2004
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Individual and Combined Effects of Age, Breast Density, and Hormone Replacement Therapy Use on the Accuracy of Screening MammographyAnnals of Internal Medicine, 2003
- Does This Patient Have Breast Cancer?JAMA, 1999
- Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-upHuman Pathology, 1998